CYP3A4 and kidney disorder: NMV/r is contraindicated for co-administration with several drugs, including antiarrhythmic, anticancer, and anticonvulsant drugs, owing to its highly dependent CYP3A4 clearance, and dose adjustment is needed in patients with kidney disorders.